WuXi Biologics

Activities: Drug Delivery Pharmaceutical

Trending Articles

  1. Combustible dust in pharma: An elusive but very real risk Controlling contamination and controlling hazards simultaneously in today's cleanrooms is difficult, sometimes even oppositional. Many operations have serious gaps that are...
  2. GMP Annex 1: Validation of disinfectants on cleanroom surfaces Published in August 2022, for implementation in August 2023, Karen Rossington from Contec looks at the revised version of EU GMP Annex 1 expanded and clarified the regulatory...
  3. Guardtech Group win fourth award in two months with Cleancube shipping container facility innovation The Suffolk-based cleanroom construction specialists secure Innovation triumph at the National Building Construction Awards
  4. Integrity testing of HEPA filters: A practical approach Filtering the air in aseptic process areas is critical to maintaining the cleanliness of the production environment. Jesus Casas provides tips to ensure HEPA filters are fit...
  5. What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification

Upcoming event

Pharmig Annual Pharmaceutical Microbiology Conference

20–21 November 2024 | Conference | Nottingham, UK See all

Related Content

Pharmaceutical

WuXi Biologics plans to build a comprehensive CRDMO centre in Singapore

This investment will establish a cutting-edge, fully integrated CRDMO centre in Singapore and strenghten WuXi Biologics’ global research, development and manufacturing network
Design & Build

WuXi Biologics closes deal to build biomanufacturing hub in the US

China-based WuXi Biologics has agreed to build its 107,000 sqft clinical and commercial manufacturing facility in Worcester, US
Design & Build

WuXi completes weather-tight seal of Irish biologics facility

WuXi Biologics has completed the seal of its first global supply facility in Europe that began construction in February 2019
Design & Build

WuXi invests $240m in Irish CDMO operations

WuXi Vaccines, a subsidiary of China-based WuXi Biologics, will spend $240m to build a dedicated vaccine manufacturing facility
Design & Build

WBDC demolishes hospital for WuXi potential biomanufacturing centre

Worcester Business Development Corp has received $15m from the state to demolish the 380,000 sqft section of a vacant hospital in Massachusetts
Manufacturing

WuXi Biologics CEO: Vaccine CDMO is the next area of growth

Dr Chris Chen launches WuXi Vaccines, announces new facility and a 20-year manufacturing contract worth US$3 billion
Research & Development

Swiss NBE-Therapeutics chooses WuXi Biologics as manufacturing partner

Chinese-Swiss partnership will focus on development and manufacturing capacity of immune-stimulatory ADC treatment against the ROR1 cancer target
Subscribe now